Archive: 20/06/2016

Osimertinib in lung cancer: Added benefit not proven

Osimertinib has been approved since February 2016 for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC). ...

page 5 from 10